ResMed is approaching its upcoming earnings report with Wall Street projecting quarterly earnings of $2.90 per share and revenue of about $1.46 billion. The stock has rebounded recently, posting a 7-day share price return of 4.55% and a 90-day return of 8.28%, though the year-to-date return remains down 8.49% and the one-year total shareholder return has declined 19.34%. A widely followed narrative values ResMed at $247.93 per share, framing the stock as modestly undervalued relative to its last close of $224.03, supported by growth in home-based, cloud-connected therapy solutions and digital health platforms that enhance recurring high-margin revenue. However, risks include competitive pressure from GLP-1 therapies, a potential re-entry by Philips Respironics, and tighter reimbursement policies that could weigh on device demand and pricing.
ResMed IncUpcoming earnings report with projected EPS and revenue, plus analyst valuation framing stock as undervalued.
